Re-administration of platinum-based chemotherapy for recurrent endometrial cancer: an ancillary analysis of the SGSG-012/GOTIC-004/Intergroup study.

Nagao, Shoji; Nishio, Shin; Takehara, Kazuhiro; Sato, Shinya; Satoh, Toyomi; Shimada, Muneaki; Yamaguchi, Satoshi; Tanabe, Hiroshi; Takano, Masashi; Horie, Kouji; Takei, Yuji; Imai, Yuichi; Hibino, Yumi; Hasegawa, Kosei; Takekuma, Munetaka; Nakamura, Kazuto; Takano, Hirokuni; Fujiwara, Keiichi; Masuyama, Hisashi

Background: We previously demonstrated the applicability of the concept of "platinum sensitivity" in recurrent endometrial cancer. Although immune checkpoint inhibitors have been widely incorporated into endometrial cancer treatment, the debate continues regarding treatment options in patients with recurrent endometrial cancer who have previously received platinum-based chemotherapy. In this study, we assessed the duration of response to secondary platinum-based treatment using pooled data from the SGSG-012/GOTIC-004/Intergroup study. Methods: Among the 279 participants in the SGSG-012/GOTIC-004/Intergroup study wherein platinum-based chemotherapy was re-administered for managing recurrent endometrial cancer between January 2005 and December 2009, 130 (47%) responded to chemotherapy. We compared the relationship between platinum-free interval and duration of secondary platinum-based treatment using pooled data. Results: In 40 patients (31%), the duration of response to secondary platinum-based treatment exceeded the platinum-free interval. The duration of response to secondary platinum-based treatment exceeded 12 months in 51 patients (39%) [platinum-free interval: < 12 months, 14/48 (29%); 12–23 months, 18/43 (42%); 24–35 months, 8/19 (42%); ≥ 36 months, 11/20 (55%)]. In particular, in eight patients (6%), the duration of response to secondary platinum-based treatment exceeded 36 months [platinum-free interval: < 12 months, 3/48 (6%); 12–23 months, 0/19 (0%); 24–35 months, 2/19 (11%); ≥ 36 months, 3/20 (15%)]. Conclusions: Re-administration of platinum-based chemotherapy for recurrent endometrial cancer may result in a long-term response exceeding the platinum-free interval in some patients. Even in the current situation, where immune checkpoint inhibitors have been introduced, re-administration of platinum-based chemotherapy is worth considering.

IMMUNE checkpoint inhibitors; ENDOMETRIAL cancer; CANCER treatment; CANCER chemotherapy; PLATINUM

International Journal of Clinical Oncology, 2024, Vol 29, Issue 10, p1594

1341-9625

Academic Journal

10.1007/s10147-024-02585-1